Current Affiliation Organization 【 display / non-display 】

Current Affiliation Organization 【 display / non-display 】

University 【 display / non-display 】

University 【 display / non-display 】

Graduate School 【 display / non-display 】

Graduate School 【 display / non-display 】

External Career 【 display / non-display 】

External Career 【 display / non-display 】

display all >>

Affiliated academic organizations 【 display / non-display 】

Affiliated academic organizations 【 display / non-display 】

display all >>

Research Areas 【 display / non-display 】

Research Areas 【 display / non-display 】

Published Papers 【 display / non-display 】

Published Papers 【 display / non-display 】

• Perspectives on genetic studies of type 2 diabetes from the genome-wide association studies era to precision medicine

  Imamura M, Maeda S

  Journal of Diabetes Investigation ( John Wiley & Sons Australia, Ltd )  15 ( 4 ) 410 - 422   2024.01 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  • Access this article
    DOI

• Natural Selection Signatures in the Hondo and Ryukyu Japanese Subpopulations

  Liu X, Matsunami M, Horikoshi M, Ito S, Ishikawa Y, Suzuki K, Momozawa Y, Niida S, Kimura R, Ozaki K, Maeda S, Imamura M, Terao C

  Molecular Biology and Evolution ( Oxford University Press )  40 ( 10 ) msad231 - msad231   2023.10 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  • Access this article
    DOI

• Demographic history of Ryukyu islanders at the southern part of the Japanese Archipelago inferred from whole-genome resequencing data

  Koganebuchi K, Matsunami M, Imamura M, Kawai Y, Hitomi Y, Tokunaga K, Maeda S, Ishida H, Kimura R

  Journal of Human Genetics ( Nature Publishing Group )  68 ( 11 ) 759 - 767   2023.07 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  • Access this article
    DOI

• Profile of gut microbiota and serum metabolites associated with metabolic syndrome in a remote island most afflicted by obesity in Japan.

  Uema T, Millman JF, Okamoto S, Nakamura T, Yamashiro K, Uehara M, Honma KI, Miyazato M, Ashikari A, Saito S, Maeda S, Imamura M, Ishida H, Matsushita M, Nakamura K, Masuzaki H

  Scientific reports ( Scientific Reports )  12 ( 1 ) 17292   2022.10 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  　View Summary

  Abstract Numerous studies have revealed distinct differences in the profiles of gut microbiota between non-obese and obese individuals. To date, however, little is known if any disparities in the community of gut microbiota exist between metabolically healthy obese (MHO) and metabolically unhealthy obese (MUO) subjects. We therefore aimed to comprehensively characterize the gut microbiota and circulating metabolites in serum from both MHO and MUO residing in the remote island, Kumejima, where the prevalence of obesity is one of the highest in Japan, and explored possible correlations between the gut microbiota profile and markers of metabolic syndrome. Results revealed that MUO showed significantly higher levels of genera such as g_Succinivibrio, g_Granulicatella, g_Brachyspira, g_Oribacterium and g_Atopobium in comparison to MHO. Moreover, abundance of g_Succinivibrio, g_Brachyspira and g_Atopobium were positively correlated with value of fasting insulin, HOMA-R, circulating triglycerides, diastolic blood pressure, BMI, body weight, waist circumference and HbA1c. In addition, MUO compared to MHO showed an imbalance of serum metabolites, with a significant elevation in 2-oxoisovaleric acid, pyruvic acid, 2-hydroxybutyric acid, and creatine. Our data highlight unmet needs in precision approaches for the treatment of obesity, targeting the gut microbiota profile and serum metabolites in a distinct population affected by obesity.

  • Access this article
    DOI
  • Search related information
    PubMed

• Impact of anti-diabetic sodium-glucose cotransporter 2 inhibitors on tumor growth of intractable hematological malignancy in humans.

  Nakachi S, Okamoto S, Tamaki K, Nomura I, Tomihama M, Nishi Y, Fukushima T, Tanaka Y, Morishima S, Imamura M, Maeda S, Tsutsui M, Matsushita M, Masuzaki H

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie ( Biomedicine and Pharmacotherapy )  149   112864 - 112864   2022.05 [ Peer Review Accepted ]

  Type of publication: Research paper (scientific journal)

  • Access this article
    DOI
  • Search related information
    PubMed

display all >>

Books 【 display / non-display 】

Books 【 display / non-display 】

• Genome-wide association study for type 2 diabetes

  Imamura M. ( Part: Allotment Writing )

  Genome-Wide Association Studies  2019.01

Other Papers 【 display / non-display 】

Other Papers 【 display / non-display 】

• Human genetics of Type 2 Diabetes and Its Clinical Implications

  Imamura Minako

  Journal of the Japan Diabetes Society ( THE JAPAN DIABETES SOCIETY )  65 ( 4 ) 179 - 182   2022.04

   

  DOI CiNii Research

• Susceptible Genes for Diabetic Retinopathy

  Imamura Minako, Maeda Shiro

  Journal of the Japan Diabetes Society ( THE JAPAN DIABETES SOCIETY )  62 ( 11 ) 702 - 706   2019

   

  DOI CiNii Research

Grant-in-Aid for Scientific Research 【 display / non-display 】

Grant-in-Aid for Scientific Research 【 display / non-display 】

• Grant-in-Aid for Scientific Research(C)

  Project Year: 2020.04  -  2023.03 

  Direct: 3,300,000 (YEN)  Overheads: 4,290,000 (YEN)  Total: 990,000 (YEN)

• Identification of novel therapeutic target for type 2 diabetes through genome-based drug discovery

  Grant-in-Aid for Scientific Research(C)

  Project Year: 2017.04  -  2020.03 

  Investigator(s): Imamura Minako 

  Direct: 3,500,000 (YEN)  Overheads: 4,550,000 (YEN)  Total: 1,050,000 (YEN)

  　View Summary

  Genome-wide association studies (GWAS) have identified more than 200 genetic loci associated with susceptibility for type 2 diabetes (T2D). We have previously proposed several new potential pharmacological targets for T2D treatments using systematic bioinformatics approach integrating the findings of GWAS for T2D, and biological or pharmacological information from various databases. KIF11 is one of the potential therapeutic targets identified by the in silico pipeline. We have demonstrated that administration of KIF11 inhibitor ameliorated impaired glucose tolerance on db/db mice through increasing the insulin sensitivity and suppressing hepatic glucose production. The results suggest that our GWAS-based drug discovery platform is useful to identify novel drug targets for the treatment of common diseases, such as T2D.

• Functional analysis of GWAS-derived type 2 diabetes susceptibility genes

  Grant-in-Aid for Scientific Research(C)

  Project Year: 2014.04  -  2017.03 

  Investigator(s): IMAMURA Minako 

  Direct: 3,800,000 (YEN)  Overheads: 4,940,000 (YEN)  Total: 1,140,000 (YEN)

  　View Summary

  We have performed a fine-mapping within the C2CD4A-C2CD4B locus to identify causal variants for type 2 diabetes susceptibility. The most significant association was observed in intergenic region which indicates the causal variant may affect the expression of either C2CD4A or C2CD4B. We also found that these genes dominantly expressed in human pancreas and mouse pancreatic beta cell line. Motivated by the results of fine mapping and expression analysis, we have generated beta-cell specific transgenic mice for C2cd4a and C2cd4b respectively to evaluate the role of these genes in vivo.

Social Activity 【 display / non-display 】

Social Activity 【 display / non-display 】

• 2023.09